Product Licensing

BN ImmunoTherapeutics inlicenses technology for breast cancer vaccine

Published in Vaccine Weekly, April 6th, 2005

Pharmexa and BN ImmunoTherapeutics, a subsidiary of Bavarian Nordic, have entered into an agreement whereby BN ImmunoTherapeutics inlicenses Pharmexa's HER-2 DNA AutoVac vaccine technology for use in a new breast cancer vaccine.

Pharmexa entered into an agreement with BN ImmunoTherapeutics, a subsidiary of Bavarian Nordic, whereby BN ImmunoTherapeutics obtains a worldwide nonexclusive license to formulate Pharmexa's HER-2 DNA AutoVac therapeutic vaccine technology against breast cancer in their MVA-BN vector. The new agreement amends the previous agreement between Pharmexa and Bavarian Nordic announced in October 2003.

Under the new agreement, BN...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry